Suggested remit: To appraise the clinical and cost effectiveness of slow-release potassium bicarbonate and potassium citrate within its marketing authorisation for treating distal renal tubular acidosis.
 
Status Awaiting development
Process STA 2018
ID number 3787

Provisional Schedule

Expected publication 17 August 2022

Project Team

Project lead Gavin Kenny

Email enquiries

Consultees

Companies sponsors Advicenne (Sibnayal)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Professional groups Renal Association
  Royal College of Physicians

Commentators

Comparator companies • Alturix (potassium bicarbonate) (confidentiality agreement not signed, not participating)
  • Aspire Pharma (sodium bicarbonate) (confidentiality agreement not signed, not participating)
  • Baxter Healthcare (citric acid, sodium citrate, sodium bicarbonate, potassium citrate) (confidentiality agreement not signed, not participating)
  • Casen Recordati (citric acid) (confidentiality agreement not signed, not participating)
  • Ennogen (sodium bicarbonate) (confidentiality agreement not signed, not participating)
  • Ethypharm (sodium citrate, sodium bicarbonate) (confidentiality agreement not signed, not participating)
  • Ferring Pharmaceuticals (citric acid) (confidentiality agreement not signed, not participating)
  • Forum/Barentz (sodium bicarbonate, potassium bicarbonate) (confidentiality agreement not signed, not participating)
  • Galen (sodium bicarbonate) (confidentiality agreement not signed, not participating)
  • GlaxoSmithKline (citric acid, sodium bicarbonate) (confidentiality agreement not signed, not participating)
  • Mylan (sodium bicarbonate) (confidentiality agreement not signed, not participating)
  • Norgine (sodium bicarbonate) (confidentiality agreement not signed, not participating)
  • ParaPharm Development (citric acid, sodium bicarbonate) (confidentiality agreement not signed, not participating)
  • Pinewood Healthcare (citric acid, sodium citrate, sodium bicarbonate) (confidentiality agreement not signed, not participating)
  • Recipharm (sodium citrate) (confidentiality agreement not signed, not participating)
  • Sanofi (sodium citrate, potassium citrate) (confidentiality agreement not signed, not participating)
  • Stirling Anglian Pharmaceuticals (sodium bicarbonate) (confidentiality agreement not signed, not participating)
  • Teva (sodium bicarbonate) (confidentiality agreement not signed, not participating)
  • Thame Laboratories (sodium bicarbonate) (confidentiality agreement not signed, not participating)
  • Thornton & Ross (citric acid, sodium bicarbonate, potassium citrate) (confidentiality agreement not signed, not participating)
  • Tillotts Pharma (sodium bicarbonate) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
11 May 2021 Invitation to participate
16 March 2021 (10:00) Scoping workshop
22 January 2021 - 19 February 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance